People · Operator
Named in public records as an officer, director or promoter · active 2017–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CeleCor Therapeutics, Inc. | — | Biotechnology | Series C | $71.5M | $994.8M | 2017 |
Robert S. Hillman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert S. Hillman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter B. Finn | 1 | 11 |
| Robert Hillman | 1 | 3 |
| Jack B. Lief | 1 | 1 |
| Andreas B. Ritzi | 1 | 1 |
| Andreas S. Ritzi | 1 | 1 |
| Caspar F.V. Sturm | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.